Although off-target binding of [18F]-S16 was observed in the basal ganglia in the HC subjects, relatively good discrimination abilities between the PSP and HC subjects were demonstrated due to the greater than expected [18F]-S16 accumulation in the regional pattern of tau pathology in the clinical diagnosis of the PSP patient, which was consistent with findings from [18F]-AV1451 and [18F]-THK5317 studies (Brendel et al., 2017; Cho et al., 2017; Schonhaut et al., 2017). This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.